D.E. Shaw & Co Portfolio holdings
D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.
Top Buys
| 1 |
SPDR S&P 500 ETF Trust
SPY
|
+$3.68B |
| 2 |
Boeing
BA
|
+$959M |
| 3 |
iShares Core S&P 500 ETF
IVV
|
+$875M |
| 4 |
Tesla
TSLA
|
+$835M |
| 5 |
Eli Lilly
LLY
|
+$643M |
Top Sells
| 1 |
NVIDIA
NVDA
|
+$939M |
| 2 |
Palantir
PLTR
|
+$668M |
| 3 |
Apple
AAPL
|
+$644M |
| 4 |
Workday
WDAY
|
+$525M |
| 5 |
Spotify
SPOT
|
+$451M |
Sector Composition
| 1 | Technology | 20.55% |
| 2 | Consumer Discretionary | 13.27% |
| 3 | Healthcare | 12.29% |
| 4 | Financials | 8.39% |
| 5 | Industrials | 7.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2551
Iovance Biotherapeutics
IOVA
$876M
| $228K | ﹤0.01% |
30,812
-36,936
| -55% | -$273K |
|
2552
Editas Medicine
EDIT
$244M
| $228K | ﹤0.01% |
179,515
-5,200
| -3% | -$6.6K |
|
|
EDR
2553
DELISTED
Endeavor Group Holdings, Inc.
EDR
| $228K | ﹤0.01% |
7,275
-142,765
| -95% | -$4.47M |
|
2554
Invesco FTSE RAFI US 1000 ETF
PRF
$8.21B
| $227K | ﹤0.01% |
5,623
-8,363
| -60% | -$337K |
|
2555
Fortrea Holdings
FTRE
$929M
| $226K | ﹤0.01% |
+12,100
| New | +$226K |
|
2556
Kodak
KODK
$485M
| $225K | ﹤0.01% |
34,313
+19,632
| +134% | +$129K |
|
2557
First Trust Water ETF
FIW
$1.94B
| $225K | ﹤0.01% |
2,201
| – | – |
|
2558
First Trust Materials AlphaDEX Fund
FXZ
$220M
| $225K | ﹤0.01% |
3,952
-1,605
| -29% | -$91.2K |
|
2559
Invesco S&P Ultra Dividend Revenue ETF
RDIV
$856M
| $224K | ﹤0.01% |
4,650
-3,131
| -40% | -$151K |
|
2560
Adverum Biotechnologies
ADVM
$65.9M
| $222K | ﹤0.01% |
+47,614
| New | +$222K |
|
2561
Preferred Bank
PFBC
$1.17B
| $222K | ﹤0.01% |
2,574
-3,596
| -58% | -$311K |
|
2562
Burford Capital
BUR
$2.84B
| $222K | ﹤0.01% |
17,433
-79,708
| -82% | -$1.02M |
|
2563
Texas Pacific Land
TPL
$21.6B
| $221K | ﹤0.01% |
+200
| New | +$221K |
|
2564
Autohome
ATHM
$3.5B
| $221K | ﹤0.01% |
8,519
-1,424
| -14% | -$37K |
|
2565
Protagonist Therapeutics
PTGX
$3.71B
| $220K | ﹤0.01% |
5,704
-21,121
| -79% | -$815K |
|
2566
Horizon Technology Finance
HRZN
$296M
| $220K | ﹤0.01% |
+24,447
| New | +$220K |
|
2567
First Trust Large Cap Value AlphaDEX Fund
FTA
$1.16B
| $219K | ﹤0.01% |
2,864
-1,317
| -31% | -$101K |
|
2568
SPDR S&P China ETF
GXC
$503M
| $218K | ﹤0.01% |
+2,873
| New | +$218K |
|
2569
Plug Power
PLUG
$1.74B
| $218K | ﹤0.01% |
102,266
+84,524
| +476% | +$180K |
|
2570
iShares Global REIT ETF
REET
$3.93B
| $218K | ﹤0.01% |
+9,078
| New | +$218K |
|
2571
Savara
SVRA
$620M
| $217K | ﹤0.01% |
70,560
+53,547
| +315% | +$164K |
|
|
LENZ
2572
LENZ Therapeutics
LENZ
$1.16B
| $215K | ﹤0.01% |
+7,447
| New | +$215K |
|
2573
BlackRock Capital Allocation Term Trust
BCAT
$1.59B
| $214K | ﹤0.01% |
14,146
-4,092
| -22% | -$62K |
|
|
VERV
2574
DELISTED
Verve Therapeutics
VERV
| $214K | ﹤0.01% |
+37,984
| New | +$214K |
|
2575
Delek US
DK
$1.72B
| $214K | ﹤0.01% |
11,579
-60,729
| -84% | -$1.12M |
|